What to expect when you take Cefuroxime axetil and Zantac 75?

Do you take Cefuroxime axetil and Zantac 75? Find out below what new side effects and undetected conditions people who are 50-59 years old may have. This prediction is created after we perform predictive analysis on health care big data. It will be updated regularly.

How to use this study: bring a copy to your health teams to ensure drug risks and benefits are fully discussed and understood.

Who is eHealthMe: we are a data analysis company who specializes in health care industry. Our original studies have been referenced on 500+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and EANO. On eHealthMe, you can research drugs and monitor them (see testimonials). If you find eHealthMe useful, please help us to spread the words below or leave us a testimonial.



On Jan, 10, 2019

9,638 reports have been studied.


Females aged 50 to 59 :

5,939 related reports were analyzed:

Most common symptoms:

Abdominal pain
  • 8.96% for females aged 50 (±5) who take Cefuroxime axetil
Acute kidney failure
  • 7.46% for females aged 50 (±5) who take Cefuroxime axetil
Anaemia
  • 11.94% for females aged 50 (±5) who take Cefuroxime axetil
Appendicitis
  • 6.18% for females aged 50 (±5) who take Cefuroxime axetil
Aptyalism
  • 5.97% for females aged 50 (±5) who take Cefuroxime axetil
Asthma
  • 6.4% for females aged 50 (±5) who take Cefuroxime axetil
Atelectasis
  • 5.33% for females aged 50 (±5) who take Cefuroxime axetil
Back pain
  • 5.97% for females aged 50 (±5) who take Cefuroxime axetil
Bone disorder
  • 6.4% for females aged 50 (±5) who take Cefuroxime axetil
Bone erosion
  • 5.97% for females aged 50 (±5) who take Cefuroxime axetil
Bone fragmentation
  • 5.97% for females aged 50 (±5) who take Cefuroxime axetil
Bone pain
  • 7.46% for females aged 50 (±5) who take Cefuroxime axetil
Bronchitis
  • 5.33% for females aged 50 (±5) who take Cefuroxime axetil
Cellulitis
  • 6.4% for females aged 50 (±5) who take Cefuroxime axetil
Chest pain
  • 7.68% for females aged 50 (±5) who take Cefuroxime axetil
  • 7.04% for females aged 50 (±5) who take Zantac 75
Deep venous thrombosis
  • 5.12% for females aged 50 (±5) who take Cefuroxime axetil
Dental caries
  • 5.97% for females aged 50 (±5) who take Cefuroxime axetil
Depression
  • 9.17% for females aged 50 (±5) who take Cefuroxime axetil
Diarrhea
  • 13.22% for females aged 50 (±5) who take Cefuroxime axetil
  • 6.64% for females aged 50 (±5) who take Zantac 75
Diverticulum
  • 8.53% for females aged 50 (±5) who take Cefuroxime axetil
Dizziness
  • 5.69% for females aged 50 (±5) who take Zantac 75
  • 5.54% for females aged 50 (±5) who take Cefuroxime axetil
Drug hypersensitivity
  • 9.81% for females aged 50 (±5) who take Cefuroxime axetil
Drug ineffective
  • 5.96% for females aged 50 (±5) who take Zantac 75
Dyspnea
  • 6.36% for females aged 50 (±5) who take Zantac 75
  • 5.97% for females aged 50 (±5) who take Cefuroxime axetil
Enteritis
  • 5.97% for females aged 50 (±5) who take Cefuroxime axetil
Enterococcal infection
  • 5.97% for females aged 50 (±5) who take Cefuroxime axetil
Escherichia infection
  • 5.97% for females aged 50 (±5) who take Cefuroxime axetil
Essential thrombocythaemia
  • 5.97% for females aged 50 (±5) who take Cefuroxime axetil
Exostosis
  • 8.53% for females aged 50 (±5) who take Cefuroxime axetil
Facial neuralgia
  • 5.97% for females aged 50 (±5) who take Cefuroxime axetil
Fall
  • 5.97% for females aged 50 (±5) who take Cefuroxime axetil
  • 5.34% for females aged 50 (±5) who take Zantac 75
Fatigue
  • 11.73% for females aged 50 (±5) who take Cefuroxime axetil
  • 7.22% for females aged 50 (±5) who take Zantac 75
Fever
  • 10.87% for females aged 50 (±5) who take Cefuroxime axetil
  • 5.21% for females aged 50 (±5) who take Zantac 75
Foot fracture
  • 6.61% for females aged 50 (±5) who take Cefuroxime axetil
Gastroesophageal reflux disease
  • 11.51% for females aged 50 (±5) who take Cefuroxime axetil
Generalised oedema
  • 5.97% for females aged 50 (±5) who take Cefuroxime axetil
Gingival infection
  • 5.97% for females aged 50 (±5) who take Cefuroxime axetil
Gingival pain
  • 5.97% for females aged 50 (±5) who take Cefuroxime axetil
Gingivitis
  • 5.97% for females aged 50 (±5) who take Cefuroxime axetil
Gums - swollen
  • 5.97% for females aged 50 (±5) who take Cefuroxime axetil
Haemangioma
  • 5.97% for females aged 50 (±5) who take Cefuroxime axetil
Headache
  • 6.61% for females aged 50 (±5) who take Cefuroxime axetil
  • 6.44% for females aged 50 (±5) who take Zantac 75
Hiatal hernia
  • 5.33% for females aged 50 (±5) who take Cefuroxime axetil
Humerus fracture
  • 5.76% for females aged 50 (±5) who take Cefuroxime axetil
Hypoaesthesia
  • 7.04% for females aged 50 (±5) who take Cefuroxime axetil
Hypotension
  • 5.12% for females aged 50 (±5) who take Cefuroxime axetil
Injury
  • 7.25% for females aged 50 (±5) who take Cefuroxime axetil
Intervertebral disc degeneration
  • 6.61% for females aged 50 (±5) who take Cefuroxime axetil
Intervertebral disc protrusion
  • 6.82% for females aged 50 (±5) who take Cefuroxime axetil
Joint dislocation
  • 5.76% for females aged 50 (±5) who take Cefuroxime axetil
Joint pain
  • 6.61% for females aged 50 (±5) who take Cefuroxime axetil
Lung disorder
  • 6.18% for females aged 50 (±5) who take Cefuroxime axetil
Malocclusion
  • 5.97% for females aged 50 (±5) who take Cefuroxime axetil
Metastatic neoplasm
  • 7.46% for females aged 50 (±5) who take Cefuroxime axetil
Mouth ulcers
  • 6.18% for females aged 50 (±5) who take Cefuroxime axetil
Nasal congestion
  • 5.12% for females aged 50 (±5) who take Cefuroxime axetil
Nausea
  • 14.07% for females aged 50 (±5) who take Cefuroxime axetil
  • 10.93% for females aged 50 (±5) who take Zantac 75
Nausea and vomiting
  • 6.31% for females aged 50 (±5) who take Zantac 75
  • 5.33% for females aged 50 (±5) who take Cefuroxime axetil
Oedema peripheral
  • 9.81% for females aged 50 (±5) who take Cefuroxime axetil
Osteitis
  • 5.97% for females aged 50 (±5) who take Cefuroxime axetil
Osteoarthritis
  • 8.53% for females aged 50 (±5) who take Cefuroxime axetil
Osteolysis
  • 5.97% for females aged 50 (±5) who take Cefuroxime axetil
Osteomyelitis
  • 8.1% for females aged 50 (±5) who take Cefuroxime axetil
Osteonecrosis of jaw
  • 9.81% for females aged 50 (±5) who take Cefuroxime axetil
Osteopenia
  • 9.38% for females aged 50 (±5) who take Cefuroxime axetil
Osteoporosis
  • 9.81% for females aged 50 (±5) who take Cefuroxime axetil
Otitis externa
  • 5.12% for females aged 50 (±5) who take Cefuroxime axetil
Paget's disease
  • 5.97% for females aged 50 (±5) who take Cefuroxime axetil
Pain
  • 19.19% for females aged 50 (±5) who take Cefuroxime axetil
  • 6.36% for females aged 50 (±5) who take Zantac 75
Pain in jaw
  • 6.4% for females aged 50 (±5) who take Cefuroxime axetil
Periodontal disease
  • 5.97% for females aged 50 (±5) who take Cefuroxime axetil
Periodontitis
  • 5.97% for females aged 50 (±5) who take Cefuroxime axetil
Platelet count increased
  • 5.12% for females aged 50 (±5) who take Cefuroxime axetil
Pleural effusion
  • 12.37% for females aged 50 (±5) who take Cefuroxime axetil
Pneumonia
  • 9.59% for females aged 50 (±5) who take Cefuroxime axetil
Poor dental condition
  • 6.4% for females aged 50 (±5) who take Cefuroxime axetil
Pulpitis dental
  • 5.97% for females aged 50 (±5) who take Cefuroxime axetil
Rashes
  • 5.76% for females aged 50 (±5) who take Cefuroxime axetil
  • 5.56% for females aged 50 (±5) who take Zantac 75
Rotator cuff syndrome
  • 6.18% for females aged 50 (±5) who take Cefuroxime axetil
Sepsis
  • 6.61% for females aged 50 (±5) who take Cefuroxime axetil
Sinusitis
  • 12.58% for females aged 50 (±5) who take Cefuroxime axetil
Spinal osteoarthritis
  • 6.4% for females aged 50 (±5) who take Cefuroxime axetil
Stomatitis
  • 6.18% for females aged 50 (±5) who take Cefuroxime axetil
Stress and anxiety
  • 15.35% for females aged 50 (±5) who take Cefuroxime axetil
Swallowing difficulty
  • 5.76% for females aged 50 (±5) who take Cefuroxime axetil
Swelling
  • 7.25% for females aged 50 (±5) who take Cefuroxime axetil
Swelling face
  • 7.25% for females aged 50 (±5) who take Cefuroxime axetil
Systemic lupus erythematosus
  • 6.82% for females aged 50 (±5) who take Cefuroxime axetil
Systemic sclerosis (scleroderma)
  • 6.4% for females aged 50 (±5) who take Cefuroxime axetil
Thrombocytosis
  • 7.46% for females aged 50 (±5) who take Cefuroxime axetil
Tooth abscess
  • 6.82% for females aged 50 (±5) who take Cefuroxime axetil
Tooth disorder
  • 5.97% for females aged 50 (±5) who take Cefuroxime axetil
Tooth extraction
  • 6.82% for females aged 50 (±5) who take Cefuroxime axetil
Tooth injury
  • 6.18% for females aged 50 (±5) who take Cefuroxime axetil
Traumatic injury of the bladder and urethra
  • 5.97% for females aged 50 (±5) who take Cefuroxime axetil
Tricuspid valve incompetence
  • 7.25% for females aged 50 (±5) who take Cefuroxime axetil
Tympanic membrane disorder
  • 5.97% for females aged 50 (±5) who take Cefuroxime axetil
Ulcerative colitis
  • 6.4% for females aged 50 (±5) who take Cefuroxime axetil
Urine output - decreased
  • 5.97% for females aged 50 (±5) who take Cefuroxime axetil
Uterine leiomyoma
  • 5.97% for females aged 50 (±5) who take Cefuroxime axetil
Vasculitis
  • 5.97% for females aged 50 (±5) who take Cefuroxime axetil
Vitreous detachment
  • 5.33% for females aged 50 (±5) who take Cefuroxime axetil
Weakness
  • 9.38% for females aged 50 (±5) who take Cefuroxime axetil
  • 6.16% for females aged 50 (±5) who take Zantac 75
Wegener's granulomatosis
  • 5.97% for females aged 50 (±5) who take Cefuroxime axetil
Weight decreased
  • 7.68% for females aged 50 (±5) who take Cefuroxime axetil
Wound infection staphylococcal
  • 5.97% for females aged 50 (±5) who take Cefuroxime axetil

Most common co-existing conditions:

Depression
  • 6.71% for females aged 50 (±5) who take Zantac 75
High blood cholesterol
  • 6.22% for females aged 50 (±5) who take Zantac 75
High blood pressure
  • 7.82% for females aged 50 (±5) who take Zantac 75
Osteoporosis
  • 7.25% for females aged 50 (±5) who take Cefuroxime axetil
Pain
  • 7.44% for females aged 50 (±5) who take Zantac 75
  • 5.54% for females aged 50 (±5) who take Cefuroxime axetil
Rheumatoid arthritis
  • 6.78% for females aged 50 (±5) who take Zantac 75
Systemic lupus erythematosus
  • 5.97% for females aged 50 (±5) who take Cefuroxime axetil
back to top

Males aged 50 to 59 :

3,699 related reports were analyzed:

Most common symptoms:

Acute myocardial infarction
  • 6.25% for males aged 50 (±5) who take Cefuroxime axetil
Anaemia
  • 5.83% for males aged 50 (±5) who take Cefuroxime axetil
Blood bilirubin increased
  • 5.0% for males aged 50 (±5) who take Cefuroxime axetil
Carpal tunnel syndrome
  • 5.42% for males aged 50 (±5) who take Cefuroxime axetil
Cellulitis
  • 7.08% for males aged 50 (±5) who take Cefuroxime axetil
Chest pain
  • 6.25% for males aged 50 (±5) who take Cefuroxime axetil
  • 5.58% for males aged 50 (±5) who take Zantac 75
Chills
  • 6.25% for males aged 50 (±5) who take Cefuroxime axetil
Coronary heart disease
  • 7.92% for males aged 50 (±5) who take Cefuroxime axetil
Cough
  • 13.75% for males aged 50 (±5) who take Cefuroxime axetil
Coughing up blood
  • 6.67% for males aged 50 (±5) who take Cefuroxime axetil
Dehydration
  • 10.0% for males aged 50 (±5) who take Cefuroxime axetil
Depression
  • 10.83% for males aged 50 (±5) who take Cefuroxime axetil
Diarrhea
  • 5.83% for males aged 50 (±5) who take Cefuroxime axetil
Drug dependence
  • 5.83% for males aged 50 (±5) who take Cefuroxime axetil
Drug withdrawal syndrome
  • 6.67% for males aged 50 (±5) who take Cefuroxime axetil
Emotional distress
  • 11.25% for males aged 50 (±5) who take Cefuroxime axetil
Fatigue
  • 14.58% for males aged 50 (±5) who take Cefuroxime axetil
  • 6.5% for males aged 50 (±5) who take Zantac 75
Fever
  • 14.17% for males aged 50 (±5) who take Cefuroxime axetil
  • 6.62% for males aged 50 (±5) who take Zantac 75
Gastroesophageal reflux disease
  • 5.83% for males aged 50 (±5) who take Cefuroxime axetil
Headache
  • 10.0% for males aged 50 (±5) who take Cefuroxime axetil
Heart attack
  • 9.17% for males aged 50 (±5) who take Cefuroxime axetil
  • 5.0% for males aged 50 (±5) who take Zantac 75
High blood cholesterol
  • 5.0% for males aged 50 (±5) who take Cefuroxime axetil
High blood pressure
  • 10.42% for males aged 50 (±5) who take Cefuroxime axetil
Hypotension
  • 6.25% for males aged 50 (±5) who take Cefuroxime axetil
Infectious mononucleosis
  • 6.25% for males aged 50 (±5) who take Cefuroxime axetil
Injury
  • 7.92% for males aged 50 (±5) who take Cefuroxime axetil
Insomnia
  • 7.08% for males aged 50 (±5) who take Cefuroxime axetil
Itching
  • 11.67% for males aged 50 (±5) who take Cefuroxime axetil
Joint pain
  • 9.17% for males aged 50 (±5) who take Cefuroxime axetil
Jugular vein thrombosis
  • 6.67% for males aged 50 (±5) who take Cefuroxime axetil
Leukocytosis
  • 7.5% for males aged 50 (±5) who take Cefuroxime axetil
Mitral valve incompetence
  • 5.42% for males aged 50 (±5) who take Cefuroxime axetil
Mitral valve prolapse
  • 5.42% for males aged 50 (±5) who take Cefuroxime axetil
Muscle cramps
  • 5.42% for males aged 50 (±5) who take Cefuroxime axetil
Nausea
  • 6.71% for males aged 50 (±5) who take Zantac 75
  • 5.0% for males aged 50 (±5) who take Cefuroxime axetil
Oedema peripheral
  • 7.92% for males aged 50 (±5) who take Cefuroxime axetil
Pain
  • 7.08% for males aged 50 (±5) who take Cefuroxime axetil
  • 5.93% for males aged 50 (±5) who take Zantac 75
Pain in extremity
  • 8.33% for males aged 50 (±5) who take Cefuroxime axetil
Pleural effusion
  • 7.5% for males aged 50 (±5) who take Cefuroxime axetil
Pneumonia
  • 6.25% for males aged 50 (±5) who take Cefuroxime axetil
Pollakiuria
  • 7.92% for males aged 50 (±5) who take Cefuroxime axetil
Pseudomonal sepsis
  • 5.83% for males aged 50 (±5) who take Cefuroxime axetil
Pulmonary congestion
  • 6.67% for males aged 50 (±5) who take Cefuroxime axetil
Pulmonary embolism
  • 5.0% for males aged 50 (±5) who take Cefuroxime axetil
Rash erythematous
  • 7.08% for males aged 50 (±5) who take Cefuroxime axetil
Rashes
  • 10.0% for males aged 50 (±5) who take Cefuroxime axetil
Renal failure acute
  • 6.25% for males aged 50 (±5) who take Cefuroxime axetil
Sinusitis
  • 6.25% for males aged 50 (±5) who take Cefuroxime axetil
Sleep apnea syndrome
  • 5.83% for males aged 50 (±5) who take Cefuroxime axetil
Squamous cell carcinoma
  • 5.42% for males aged 50 (±5) who take Cefuroxime axetil
Stable angina
  • 5.42% for males aged 50 (±5) who take Cefuroxime axetil
Stress and anxiety
  • 12.08% for males aged 50 (±5) who take Cefuroxime axetil
Thrombosis
  • 7.92% for males aged 50 (±5) who take Cefuroxime axetil
Trigger finger
  • 5.42% for males aged 50 (±5) who take Cefuroxime axetil
Weakness
  • 5.83% for males aged 50 (±5) who take Cefuroxime axetil
  • 5.2% for males aged 50 (±5) who take Zantac 75
Weight decreased
  • 5.42% for males aged 50 (±5) who take Cefuroxime axetil

Most common co-existing conditions:

High blood pressure
  • 6.13% for males aged 50 (±5) who take Zantac 75
Pain
  • 6.36% for males aged 50 (±5) who take Zantac 75
back to top

Do you take Cefuroxime axetil and Zantac 75:

  • To personalize this prediction to you, including to your gender, age, personal and family history, and more: Click here

Related studies

Cefuroxime axetil

Cefuroxime axetil has active ingredients of cefuroxime axetil. It is often used in sinusitis. (latest outcomes from Cefuroxime axetil 1,781 users)

Zantac 75

Zantac 75 has active ingredients of ranitidine hydrochloride. It is often used in gastroesophageal reflux disease. (latest outcomes from Zantac 75 1,458 users)

General study

Related publications that referenced our studies


Recent updates

Recent general studies
Recent personal studies

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on ePatient.care is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the ePatient.care site and its content is at your own risk.

Submit your testimonial

  • Please fill in your Testimonial.
  • Please enter a minimum of 10 characters for your Testimonial.
  • Please fill in your Name.

Please wait...

{progressItem}

Thank you!